Novo Nordisk Partners with OpenAI

Novo Nordisk said on April 14 it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial operations. (biospace.com) The Danish drugmaker said the system will be used to analyze large datasets, identify drug candidates and cut the time from research to patient use. Novo Nordisk said the agreement includes strict data protection, governance and human oversight. (biospace.com) Pilot programs are starting in research and development, manufacturing and commercial teams, with full integration targeted by the end of 2026. OpenAI will also help train Novo Nordisk’s workforce in artificial intelligence use. (biospace.com), (pharmaceutical-technology.com) Drug discovery starts with a basic sorting problem: researchers test huge numbers of biological signals to find a few that might become medicines. Novo Nordisk said artificial intelligence can help spot patterns in that data faster and test more hypotheses before a drug reaches patients. (cnbc.com), (biospace.com) The move lands as large drugmakers push artificial intelligence beyond research labs and into factories, supply chains and clinical development. CNBC reported that experts still see the near-term gains in practical tasks such as trial design and patient recruitment, not fully automated end-to-end drug creation. (cnbc.com) Novo Nordisk is making the bet while trying to regain momentum against Eli Lilly in obesity drugs. Reuters reported on April 14 that Novo has fallen behind Lilly in that market, and CNBC reported in February that Lilly had taken a clear edge in market share. (srnnews.com), (cnbc.com) Investors initially welcomed the announcement. CNBC reported Novo Nordisk shares were up 2.8% shortly after the opening bell on April 14. (cnbc.com) The OpenAI deal extends an existing Novo Nordisk artificial intelligence push. In June 2025, Nvidia said it was working with Novo Nordisk and the Danish Centre for AI Innovation to build custom models and agents for early research and clinical development using Denmark’s Gefion supercomputer. (investor.nvidia.com), (dcai.dk) For now, Novo Nordisk has described the partnership as a company-wide rollout with pilots first and broader deployment later in 2026. The test will be whether faster analysis in the lab and smoother work in factories and supply chains show up in actual medicines and delivery. (biospace.com), (pharmaceutical-technology.com)